# OnCo record fulvestrant (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/fulvestrant/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "fulvestrant" ;
  schema:name "Fulvestrant"@en ;
  schema:description "Fulvestrant is a monthly intramuscular injection that degrades the oestrogen receptor rather than blocking it, the endocrine backbone paired with CDK4/6, PI3K and AKT inhibitors once aromatase inhibitors fail. Slow uptake and incomplete receptor degradation drove the search for oral degraders."@en ;
  schema:url <https://onco.cc/drugs/fulvestrant/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Fulvestrant> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5508491> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Fulvestrant> ;
  onco:status "approved" ;
  onco:modality "Injectable SERD" ;
  schema:alternateName "Faslodex" ;
  onco:approval "US 2002: HR+ advanced breast cancer after antioestrogen therapy", "US 2017: First-line HR+ advanced breast cancer (FALCON)" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/capitello-291/>, <https://onco.cc/trials/inavo120/>, <https://onco.cc/trials/solar-1/>, <https://onco.cc/trials/postmonarch/>, <https://onco.cc/trials/veritac-2/>, <https://onco.cc/trials/nct06506955/>, <https://onco.cc/trials/nct06726148/>, <https://onco.cc/trials/nct05735080/>, <https://onco.cc/trials/nct04557449/>, <https://onco.cc/trials/nct07287917/>, <https://onco.cc/trials/nct04553133/>, <https://onco.cc/trials/nct04606446/>, <https://onco.cc/trials/nct07288359/>, <https://onco.cc/trials/nct05867251/>, <https://onco.cc/trials/nct07109726/>, <https://onco.cc/trials/nct04567420/>, <https://onco.cc/trials/nct05501886/>, <https://onco.cc/trials/nct05768139/>, <https://onco.cc/trials/nct06979596/>, <https://onco.cc/trials/nct06202261/>, <https://onco.cc/trials/nct06065748/>, <https://onco.cc/trials/nct06736704/>, <https://onco.cc/trials/nct02763566/>, <https://onco.cc/trials/nct07558733/>, <https://onco.cc/trials/nct06016738/>, <https://onco.cc/trials/nct05696626/>, <https://onco.cc/trials/nct07498478/>, <https://onco.cc/trials/nct06555068/>, <https://onco.cc/trials/nct06702618/>, <https://onco.cc/trials/nct02107703/>, <https://onco.cc/trials/nct06635447/>, <https://onco.cc/trials/nct06957379/>, <https://onco.cc/trials/nct05646862/>, <https://onco.cc/trials/nct00099437/>, <https://onco.cc/trials/nct04214288/>, <https://onco.cc/trials/nct07389733/>, <https://onco.cc/trials/nct04115306/>, <https://onco.cc/trials/nct05262400/>, <https://onco.cc/trials/nct05230810/>, <https://onco.cc/trials/nct06428396/>, <https://onco.cc/trials/nct06757634/>, <https://onco.cc/trials/nct07368998/>, <https://onco.cc/trials/nct04862663/>, <https://onco.cc/trials/nct04576455/>, <https://onco.cc/trials/nct05038735/>, <https://onco.cc/trials/nct07235176/>, <https://onco.cc/trials/nct04579380/>, <https://onco.cc/trials/nct05251714/>, <https://onco.cc/trials/nct04539496/>, <https://onco.cc/trials/nct06380751/>, <https://onco.cc/trials/nct06764186/>, <https://onco.cc/trials/nct04524000/>, <https://onco.cc/trials/nct06993844/>, <https://onco.cc/trials/nct07405801/>, <https://onco.cc/trials/nct04544189/>, <https://onco.cc/trials/nct05573126/>, <https://onco.cc/trials/nct05226871/>, <https://onco.cc/trials/nct04851613/> .